Open access peer-reviewed chapter

Genetic Polymorphisms and Ischemic Heart Disease

Written By

Francesco Fedele, Mariateresa Pucci and Paolo Severino

Submitted: 15 December 2016 Reviewed: 08 May 2017 Published: 06 September 2017

DOI: 10.5772/intechopen.69621

From the Edited Volume

Genetic Polymorphisms

Edited by Narasimha Reddy Parine

Chapter metrics overview

1,594 Chapter Downloads

View Full Metrics


Although the progression in diagnostic tools, prevention strategies, and therapies, ischemic heart disease still represents the major cause of mortality and morbidity worldwide that globally represents an important problem for individuals and healthcare resources. By convention, ischemic heart disease is associated with the presence of an atherosclerotic plaque that is able to limit the flow in large-medium-sized coronary arteries. Nevertheless, several findings suggest a more complex pathophysiology of ischemic heart disease. At this time, there is no well-defined assessment of myocardial ischemia pathophysiology. Moreover, several data have identified genetic variations at different loci that are linked with ischemic heart disease susceptibility. This chapter aims to examine this complicated disease and to review the evidence on the genetic heritability acting with other factors in determining the presence of ischemic heart disease, due to either an obstruction in epicardial vessels or a dysfunction of coronary microcirculation.


  • atherosclerosis
  • coronary artery disease
  • coronary microvascular disease
  • endothelial dysfunction
  • ion channel
  • ischemic heart disease
  • myocardial infarction
  • myocardial ischemia
  • risk factor
  • single-nucleotide polymorphism

1. Introduction

Nowadays, ischemic heart disease remains a major cause of death and disability worldwide for both men and women, although the evolution in prevention and therapy strategies [1]. By convention, ischemic heart disease is equated with atherosclerotic plaque due to flow-limiting obstruction in epicardial coronary arteries. Nevertheless, several findings suggest a more complex pathophysiology of this complex disease [28]. In fact, it has been showed that beyond the presence of epicardial atherosclerotic plaques, coronary microcirculation is crucial in the genesis of ischemic heart disease [9, 10]. In addition, in the last few years, a growing body of data is underlying the importance of heritability acting with other factors in order to determine the presence of ischemic heart disease, due to either an obstruction in epicardial vessels [1113] or a dysfunction of coronary microcirculation [14, 15]. In fact, over the past decade, genome-wide association studies have identified several loci, explaining a part of the ischemic heart disease’s heritability. Existing knowledge of genetic variants affecting risk of ischemic heart disease is largely based on genome-wide association studies analysis of common single-nucleotide polymorphisms.

Therefore, this chapter proposes an overview of the loci that have been identified as connected with ischemic heart disease genesis, from epicardial plaque to microvascular dysfunction.


2. Coronary artery disease

Coronary artery disease is defined by the presence of a plaque in the epicardial coronary arteries. Usually, the atherosclerotic plaque narrow coronary arteries, decreasing blood flow. In subjects with genetic susceptibility factors, coronary artery disease is determined by exposure to some risk factors. In the last years, several researches have enhanced our understanding of the risk factors as well as the genetic basis of coronary artery disease. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidemias, or non-modifiable, such as age, male gender, and genetic susceptibility.

To date, more than 50 loci have been identified for susceptibility of coronary artery disease, as described by the meta-analysis carried out by the CARDIoGRAMplusC4D Consortium, on almost 185,000 cases and controls [11]. Moreover, data from a meta-analysis of genome-wide association studies have also been carried out for conventional risk factors and biomarker for coronary artery disease, like dyslipidemia and blood pressure, diabetes mellitus, atherosclerosis, inflammation, coagulation, oxidation, and amino acid metabolism, identifying several genes for each respective factor [12].

2.1. Genetic polymorphisms and risk factors for coronary artery disease

2.1.1. Dyslipidemia

Lipid metabolism can be altered in different ways, leading to variations in plasma lipoprotein function and concentration. Through interaction with other cardiovascular risk factors, dyslipidemias may affect the development of coronary artery disease. Dyslipidemias may be related to the interaction between genetic predisposition and environmental factors. Up to the present time, 12 loci were significantly associated by genome-wide association studies with the concentrations of blood lipids and coronary artery disease. Among these, eight loci were associated with LDL concentration (ABCG5, ABCG8, ABO, APOB, APOE, LDLR, LPA PCSK9, and SORT1), two loci with triglyceride concentration (APOA5 and TRIB1), and one locus with HDL concentration (ANKS1A). At another locus, there was a near-equivalent association for triglyceride and HDL (LPL). In severely obese patients, a single-nucleotide polymorphism within the ARPC3 Gene Promoter was associated with hypertriglyceridemia [16]. Moreover, among different ethnicities Lysosomal Acid Lipase A (LIPA), polymorphisms have been described as associated with susceptibility to premature coronary artery disease [17]. APOA5 polymorphisms, air pollution, and the development of coronary artery disease have been associated, although methylation studies are needed to examine epigenetic factors associated with those single-nucleotide polymorphisms. Another interesting correlation is between TNNT1 variations, HDL levels, and coronary artery disease [15]. Finally, it has been suggested that Numb gene haplotypes, the regulating factor for intestinal cholesterol absorption and plasma cholesterol level, are related to coronary artery disease in Han Chinese [18].

2.1.2. Arterial hypertension

The relationship between blood pressure values and cardiovascular fatal events has been determined in several studies [19]. Numerous rare, monogenic forms of hypertension have been described, where a single gene mutation explains the pathogenesis of hypertension [20]. On the other side, essential hypertension is a heterogeneous disease with a multifactorial etiology. Genetic approaches raised the understanding of pathways underlying individual variations in blood pressure. Primary analyses evaluated associations between 2.5 million genotyped or imputed single-nucleotide polymorphisms (single-nucleotide polymorphisms) and SBP and DBP. Several genome-wide association studies and their meta-analyses point to a total of 29 single-nucleotide polymorphisms, which are associated with systolic and/or diastolic blood pressure [21]. In particular, latest genome-wide association studies data described four coronary artery disease risk loci (CYP17A1- NT5C2, SH2B3, ZC3HC1, GUCY1A3, and FES) associated with systolic and diastolic blood pressure [11, 21]. Moreover, endothelial nitric oxide synthase (eNOS) single-nucleotide polymorphism G894T significantly increases hypertension risk and coronary artery disease [22]. Selective expression of the Rho GTPase-activating protein ARHGAP42 in vascular smooth muscle cells regulates arterial blood pressure, as it inhibits RhoA-dependent contractility [23]. Furthermore, PDE3A, PRDM6, IGFBP3, and KCNK3 genes regulate vascular smooth muscle cells [24]. Particularly, PDE3A is phosphodiesterase acting in cyclic GMP metabolism [25], whereas KCNK3 has been related to pulmonary hypertension [26]. Other genes related to renal function have been described as acting in blood pressure regulation: ARHGAP24 influences podocyte formation [27], OSR1 influences renal mass and function [28], and SLC22A7 encodes for a renal solute transporter [29]; DNA methylation is probably involved in the regulatory pathway linking common single-nucleotide polymorphisms with blood pressure, according to data from experimental models of hypertension [30].

The single-nucleotide polymorphism Gly460Trp has been associated with hypertension and salt sensitivity [31] and an increased risk for coronary heart disease or peripheral vascular disease [32] and stroke [33]. An individual with this single-nucleotide polymorphism is a responder to diuretics better than wild-type homozygotes [31] in terms mostly of reduction of cardiovascular risk [34].

2.1.3. Diabetes mellitus

Diabetes mellitus has an increasing prevalence worldwide: 360 million people had diabetes in 2011, of which more than 95% type 2 diabetes. Diabetes mellitus is a complex, chronic disease requiring multifactorial risk-reduction strategies beyond glycemic control. Diabetes mellitus and cardiovascular disease develop with metabolic abnormalities causing dysfunction in the vasculature. Mortality and morbidity in people with diabetes are related to cardiovascular disease. Diabetes is a condition defined by an elevated level of blood glucose, and it can be classified into general categories: type 1 diabetes (due to b-cell destruction) and type 2 diabetes (due to a progressive loss of insulin secretion on the background of insulin resistance).

Usually, type 2 diabetes mellitus is more frequent with obesity, lack of physical activity, in women with prior gestational diabetes, in association with hypertension or dyslipidemia, and in certain ethnic groups. Insulin resistance plays an important role in the pathophysiology of type 2 diabetes mellitus and coronary artery disease: both genetic and environmental factors collaborate to its development. In fact, more than 90% of people with type 2 diabetes mellitus are obese [35]. Nevertheless, type 2 diabetes mellitus is often associated with a strong genetic predisposition, more so than type 1 diabetes. However, the genetics of type 2 diabetes is poorly understood. Classically, both the single-nucleotide polymorphism Pro12Ala in the peroxisome proliferator-activated receptor gamma (PPARG) gene [36] and the single-nucleotide polymorphism Glu23Lys in KCNJ11 gene [37] are common polymorphisms connected with influence risk of diabetes mellitus [38]. In particular, single-nucleotide polymorphisms for KCNJ11 have been described as involved in the susceptibility of ischemic heart disease, including coronary artery disease and CM (see below). Moreover, transcription factor 7-like 2 (TCF7L2) gene is involved in diabetes mellitus susceptibility [39]. Some single-nucleotide polymorphisms of the gene associated with fat mass and obesity (FTO) [40] have an impact on body mass index (BMI). Other single-nucleotide polymorphisms of the gene within or adjacent to hematopoietically expressed homeobox (HHEX)/insulin degrading enzyme (IDE), CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1), insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), cyclin-dependent kinase inhibitors 2a, b (CDKN2A and CDKN2B), and solute carrier family 30, member 8 (SLC30A8) have an effect on insulin secretion [4143].

Several other loci are implicated in diabetes mellitus as PPARG [44] and KCNJ11 [45] and for HNF1B (TCF2) [46] and WFS1 [47]. However, recent data suggest a possible role of other genes [48]: Notch homologue 2, Drosophila (NOTCH2) that is known to be involved in pancreatic development. Mapping within or adjacent to ADAM metallopeptidase with thrombospondin type 1 motif 9 (ADAMTS9), calcium/calmodulin-dependent protein kinase 1D (CAMK1D), compared with another zinc finger gene 1 (JAZF1), tetraspanin 8 (TSPAN8)/leucine-rich repeat containing G-protein coupled (LGR5), and thyroid adenoma associated (THADA), the mechanisms involved remain unclear [38].

2.1.4. Atherosclerosis

Cardiovascular disease due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe and is also increasingly common in developing countries. Atherosclerotic lesions (i.e., atheroma) are asymmetric focal thickenings of the innermost layer of the artery, the intima. The pathophysiology of atherosclerosis suggests an inflammatory disease characterized by arterial plaque rich in cholesterol, inflammatory cell infiltrates, and connective tissue [49]. Data from clinical researches, studies in animal models, and cell culture experiments found important evidences to the pathogenesis of atherosclerosis. Several types of research demonstrated an association of IL6R-related gene pathways with atherosclerosis and coronary artery disease [50].

In patients with established coronary artery disease, it has been showed that the −174 C allele of the IL-6 gene increases the risk for progression of coronary plaques [14]. Moreover, patients with the Cox-2 GG single-nucleotide polymorphism have a higher risk of coronary artery disease while the Cox-2 (−765G>C) polymorphism is associated with lower interleukin-6 levels [51]. Moreover, multiple single-nucleotide polymorphisms as FGB-FGA-FGG, NLRP3, IL1RN, and IRF1-SCL22A5 show a strong association with fibrinogen expression and function [52]. Analogously the plaque composition has been associated with specific genes: matrix metalloproteinase genes (MMP1, 9, 12, 14) and the co-stimulatory ligands CD80 and CD86 [53] are associated with vulnerable plaques. Moreover, indoleamine 2, 3-dioxygenase 1 (IDO1) and integrin alpha V expression levels seem to be higher in vulnerable than in stable plaques [53].

In atherosclerotic plaques, there is an overexpression of CB2 gene (CNR2), that is an inflammatory marker, compared with normal arteries, whereas stable and vulnerable plaques displayed similar CNR2 levels [53]. Lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) is the main scavenger receptor for oxidized low-density lipoprotein (ox-LDL) in endothelial cells. The single-nucleotide polymorphism c.501G>C determines a single amino acid change (K>N at codon 167) reduces ox-LDL binding and uptake. Ox-LDL activated extracellular signal-regulated kinases 1 and 2 (ERK 1/2) is inhibited [5456].


3. Coronary microvascular disease

The coronary microcirculation is often considered an underwater world beyond the epicardial arteries, often inaccessible for routine investigation, unachievable for targeted treatment. However, microcirculation is crucial in the cross talk between perfusion to myocardial demand. Pathway for coronary metabolic dilation is determining genetic associations in genes encoding for coronary blood flow regulators (i.e., ion channels, nitric oxide synthase, SERCA pump, and so on) with the susceptibility for microcirculation dysfunction and ischemic heart disease [57].

Recently, a study comparing the prevalence of single-nucleotide polymorphisms in genes encoding coronary ion channels between patients with coronary artery disease or microvascular dysfunction and those with both anatomically and functionally normal coronary arteries suggested the possibility of associations between single-nucleotide polymorphisms and ischemic heart disease in term of coronary artery disease and microvascular dysfunction [57]. In fact, data show that specific single-nucleotide polymorphisms detected in NOS3 gene encoding for endothelial nitric oxide synthase (eNOS), as well as in KCNJ8 encoding for the inward rectifying subunit of ATP-sensitive potassium channel (Kir6.2) and SCN5A encoding for voltage-dependent Na+ channel (Nav1.5) were found to be correlated with ischemic heart disease and microvascular dysfunction [58]. Specifically, the single-nucleotide polymorphisms rs5215_GG, rs5218_CT, and rs5219_AA for Kir6.2/KCJ11 could reduce susceptibility to ischemic heart disease; the single-nucleotide polymorphism rs5219_AA of Kir6.2/KCNJ11 may suggest a protecting role against coronary microvascular dysfunction; the rs1805124_GG genotype of Nav1.5/SCN5A seems to play a role in coronary artery disease. In the same study, also eNOS/NOS3 gene was investigated, demonstrating that rs1799983 polymorphism for this gene seems to be an independent risk factor for microvascular dysfunction [57]. The Transient Receptor Potential Ankyrin 1 (TRPA1) has been evaluated in vasodilation using KO mice [59]. On the other side, smooth muscle Kv7 channels have been associated with the control of vascular reactivity and vasorelaxant responses in coronary circulation [60]. To date, five subtypes of Kv7 channels encoded by KCNQ genes have been identified [61]. Kv7.1 and Kv7.4 were expressed at higher levels compared to Kv7.2, Kv7.3, and Kv7.5 in coronary arteries [62].

Regarding nitric oxide synthase, the allele “a” of intron 4a/b (eNOS4) has been described as a risk factor for patients with microvascular endothelial dysfunction and slow coronary flow [63].

Microvascular angina has been also associated with CYP2C19 variants that may affect coronary microvascular dysfunction [64]. Moreover, recent data in the female population showed that the specific CYP2C19 poor metabolizer genotype can lead to coronary microvascular disorders via inflammation [65].

Nuclear factor (erythroid-derived 2)-like-2 (NRF2) is an antioxidant and cell protective transcription factor that controls antioxidant defenses. NRF2 suppression plays an essential role in the development of oxidant stress, endothelial dysfunction, and microvessel rarefaction [66]. Moreover, Nox4 has been described as a positive transcriptional regulator of cystathionine-γ-lyase (CSE) in endothelial cells. It regulates vascular tone via the modulation of gasotransmitter, hydrogen sulfide (H2S) production [67].

Hypoxia-inducible factor-1 (HIF-1) is a peptide regulator of genes such as heme oxygenase (HO)-1 expressed during hypoxia. HIF-1 activation induces HO-1 expression attenuating proinflammatory chemokine production by microvascular endothelium in vitro and in vivo [68]. The single-nucleotide polymorphism C242T causes p22 (phox) structural changes that inhibit endothelial Nox2 activation and oxidative response to tumor necrosis factor-α or high-glucose stimulation. The single-nucleotide polymorphism C242T has been proposed a protective factor against cardiovascular diseases [69]. Novel regions of genetic variations within vascular endothelial growth factor A (VEGFA) and CDKN2B antisense RNA1 (CDKN2B-AS1) genes have been associated with coronary microvascular dysfunction. Furthermore, there were sex-specific differences in single-nucleotide polymorphisms which are associated with microvascular dysfunction, in particular, myosin heavy chain 15 (MYH15), VEGFA, and NT5E. In the male, single-nucleotide polymorphisms for NT5E are associated with abnormal coronary flow reserve; however, mutations in NT5E are associated with arterial calcification [70]. NT5E gene encodes for CD73 that transforms adenosine monophosphate (AMP) to adenosine, supporting a role for this metabolic pathway in inhibiting vascular calcification [70, 71]. In fact, lack of CD73 leads to a reduction in extracellular adenosine levels, causing vascular calcification [72].

In a meta-analysis of genome-wide association studies, data identified four novel loci on chromosomes 19q13, 6q24, 12q24, and 5q14 that were associated with retinal venular caliber. The retinal vasculature is comparable with human microcirculation. Retinal venular caliber has been shown to predict a range of subclinical [73] and clinical cardiovascular disease. RASIP1 gene (rs2287921, p = 1.61610225) on chromosome 19q13 is the most significant single-nucleotide polymorphism associated with retinal venular caliber, and the single-nucleotide polymorphisms were located in or adjacent to VTA1 and NMBR genes on chromosome 6q24. VTA1 gene encodes for a protein involved in trafficking of the multivesicular body. The signals for the association on chromosome 12q24 were spread across a large one Mb LD block, including genes such as SH2B3, ATXN2, and PTPN11. The most significant single-nucleotide polymorphisms at the 5q14 locus were located closest to MEF2C that plays an important role in cardiogenesis, epithelial cell survival, and maintenance of blood vessel integrity [74].

Finally, sarcomere gene mutations are associated with adverse remodeling of the microcirculation in hypertrophic cardiomyopathy [75, 76]. In fact, patients with hypertrophic cardiomyopathy with sarcomere myofilament mutations are characterized by more severe impairment of microvascular function and increased prevalence of myocardial fibrosis, compared with genotype-negative individuals [75].


4. Sex differences

Gender difference deserves a separate section. Scientific interest in ischemic heart disease in women has grown significantly over the past decades, mostly on clinical aspects. In fact, ischemic heart disease differs in term of pathogenesis, symptoms, and prognosis between males and females. Several studies show that different single-nucleotide polymorphisms of different genes can be involved. Single-nucleotide polymorphisms within genes of MYH15, linked to the maintenance of tonic force in vascular smooth muscle cells, VEGFA, involved in cell proliferation, migration, and angiogenic potential and NT5E which contributes to overall microvessel stiffness were associated with microvascular dysfunction in men [63, 77]. Studies on polymorphisms at the cholesteryl ester transfer protein (CETP) locus showed that women displayed a higher HDL-C than men and an equally high incidence of coronary heart disease in B2 homozygotes as in other genotypes [78]. Thus, in type 2 diabetic patients, the B polymorphism seems to exert a modulating role in males only. This may contribute to the loss of macrovascular protection in type 2 diabetic females [78].

Moreover, the specific CYP2C19 poor metabolizer has been described as a risk factor for coronary microvascular disorders via inflammation exclusively in the female population [65]. Usually, in fertile female exhibits a protection in ischemic injury compared to age-related men, a phenomenon designated as sex-specific cardioprotection. PKC-mediated regulation of sarcolemmal ATP-dependent K [sarcK(ATP)] channels may account for the gender difference in cardioprotection upon both PKC and sarcK(ATP). It involves PKC-dependent sarcolemma increase with a major expression of sarcK(ATP) in female [77]. Microcirculation dysfunction can also be associated with cardiac hypertrophy, which can be related to the expression of Kvβ1.1, particularly in females. In an animal model, Kvβ1 KO female mice have a growing myosin heavy chain α expression in myocytes. Changes in molecular and cell signaling pathways clearly point toward a distinct electrical and structural remodeling consistent with cardiac hypertrophy in the Kvβ1.1 KO female mice [79].


5. Conclusions

Ischemic heart disease is a common disease that globally represents an important problem for individuals and healthcare resources. An enhanced understanding of its pathophysiology is needed. By convention, ischemic heart disease is associated with the presence of an atherosclerotic plaque that is able to limit the flow in large-medium sized coronary arteries. Multiple different mechanisms are responsible for symptoms suggesting ischemic heart disease without apparent flow-limiting obstruction on angiography. In fact, both coronary artery disease and coronary microvascular disease can be responsible for an impaired cross talk between myocardial demand and oxygen supply. Interestingly, discordance between epicardial coronary function and microvascular function has generated recent interest. Finding no obstructive epicardial stenosis, but reduced microvascular function, indicating coronary microvascular disease, is associated with a negative prognosis [80].

In contrast, preserved microvascular function in the presence of flow-limiting epicardial stenosis has been associated with a long-term clinical outcome. In fact, several findings suggest a complex pathophysiology of ischemic heart disease. Both genetic and lifestyle factors contribute to the individual-level risk of ischemic heart disease, both coronary artery disease and coronary microvascular disease. Genetic susceptibility is determined by several single-nucleotide polymorphisms of genes encoding for both elements involved in the coronary homeostasis as well as for major risk factors for cardiovascular events (i.e., hypertension, diabetes, dyslipidemia). Genetic susceptibility is independent of healthy lifestyle behaviors and can be associated with an increased risk of coronary events, although a healthy lifestyle is associated with event risk reductions in rates.

Nowadays, associative hypothesis between single-nucleotide polymorphisms and ischemic heart disease has been numerous in literature, and, in some case, researches show speculative data with no provided plausible causal mechanism. Large-scale studies in human populations, genome-wide association studies, and meta-analysis, together with genetic technologies improvements, are helping the comprehension of genetic susceptibility of ischemic heart disease over the last decade. Moreover, a functional understanding of the discovered genetic associations with ischemic heart disease could help in the development of novel therapeutic strategies. However, we are still distant to the fully knowledge of the pathophysiology of this complex disease and the real role of heritability.


  1. 1. Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The Global burden of disease 2010 study. Circulation. 2014;129:1483-1489. DOI: 10.1161/CIRCULATIONAHA.113.004042
  2. 2. Tiefenbacher CP, Chilian WM. Heterogeneity of coronary vasomotion. Basic Research in Cardiology. 1998;93:446-454
  3. 3. Wolin MS, Ahmad M, Gupte SA. Oxidant and redox signaling in vascular oxygen sensing mechanisms: Basic concepts, current controversies, and potential importance of cytosolic NADPH. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2005;289:159-173. DOI: 10.1152/ajplung.00060.2005
  4. 4. Tune JD. Withdrawal of vasoconstrictor influences in local metabolic coronary vasodilation. The American Journal of Physiology-Heart and Circulatory Physiology. 2006;291:2044-2046. DOI: 10.1152/ajpheart.00653.2006
  5. 5. Dzeja PP, Bast P, Pucar D, et al. Defective metabolic signaling in adenylate kinase AK1 gene knock-out hearts compromises post-ischemic coronary reflow. The Journal of Biological Chemistry. 2007;282:31366-31372. DOI: 10.1074/jbc.M705268200
  6. 6. Ottaviani G, Lavezzi AM, Rossi L, Matturri L. Proliferating cell nuclear antigen (PCNA) and apoptosis in hyperacute and acute myocardial infarction. European Journal of Histochemistry. 1999;43:7-14
  7. 7. Wong B, Kruse G, Kutikova L, et al. Cardiovascular disease risk associated with familial hypercholesterolemia: A systematic review of the literature. Clinical Therapeutics. 2016;38:1696-1709. DOI: 10.1016/j.clinthera.2016.05.006
  8. 8. Feldman RD. Heart disease in women: Unappreciated challenges, GPER as a new target. International Journal of Molecular Sciences. 2016;18:17(5). DOI: 10.3390/ijms17050760
  9. 9. Komaru T, Kanatsuka H, Shirato K. Coronary microcirculation: Physiology and pharmacology. Pharmacology & Therapeutics. 2000;86:217-261. DOI:
  10. 10. Chilian WM. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation. 1997;95:522-528. DOI:
  11. 11. Deloukas P, Kanoni S, Willenborg C, for the CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nature Genetics. 2013;45:25-33. DOI: 10.1038/ng.2480
  12. 12. Nikpay M, Goel A, Won HH. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nature Genetics. 2015;47:1121-1130. DOI: 10.1038/ng.3396
  13. 13. Webb TR, Erdmann J, Stirrups KE, et al. Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease. Journal of the American College of Cardiology. 2017;21(69):823-836. DOI: 10.1016/j.jacc.2016.11.056
  14. 14. Toutouzas K, Klettas D, Anousakis-Vlachochristou N, et al. The –174 G>C interleukin-6 gene polymorphism is associated with angiographic progression of coronary artery disease in a 4-year period. Hellenic Journal of Cardiology. 2017;14:S1109-9666(16)30361-X. DOI: 10.1016/j.hjc.2017.02.002
  15. 15. Guay SP, Légaré C, Brisson D, et al. Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease. Epigenomics. 2016;8(3):359-371. DOI: 10.2217/epi.15.120
  16. 16. de Toro-Martín J, Guénard F, Tchernof A, et al. A CpG-SNP Located within the ARPC3 gene promoter is associated with hypertriglyceridemia in severely obese patients. Annals of Nutrition and Metabolism. 2016;68:203-212. DOI: 10.1159/000445358
  17. 17. Vargas-Alarcón G, Posadas-Romero C, Villarreal-Molina T, et al. Single nucleotide polymorphisms within LIPA (Lysosomal Acid Lipase A) gene are associated with susceptibility to premature coronary artery disease. A replication in the genetic of atherosclerotic disease (GEA) Mexican study. PLoS One. 2013;8(9):e74703. DOI: 10.1371/journal.pone.0074703
  18. 18. Abudoukelimu M, Fu ZY, Maimaiti A, et al. The association of cholesterol absorption gene Numb polymorphism with coronary artery disease among Han Chinese and Uighur Chinese in Xinjiang, China. Lipids in Health and Disease. 2015;14:120. DOI: 10.1186/s12944-015-0102-6
  19. 19. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913. DOI:
  20. 20. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-556. DOI:
  21. 21. International Consortium For Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109. DOI: 10.1038/nature10405
  22. 22. ALrefai AA, Habib MS, Yaseen RI, Gabr MK, Habeeb RM. Association of endothelial nitric oxide synthase (eNOS) gene G894T polymorphism with hypertension risk and complications. Molecular and Cellular Biochemistry. 2016;421:103-110. DOI: 10.1007/s11010-016-2790-2
  23. 23. Bai X, Mangum KD, Dee RA, et al. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. Journal of Clinical Investigation. 2017;127:670-680. DOI: 10.1172/JCI88899
  24. 24. Kato N, Loh M, Takeuchi F, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nature Genetics. 2015;47:1282-1293. DOI: 10.1038/ng.3405
  25. 25. Beca S, et al. Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circulation Research. 2013;112:289-297. DOI: 10.1161/CIRCRESAHA.111.300003
  26. 26. Ma L, et al. A novel channelopathy in pulmonary arterial hypertension. The New England Journal of Medicine. 2013;369:351-361. DOI: 10.1056/NEJMc1311060#SA2
  27. 27. Akilesh S, et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. Journal of Clinical Investigation. 2011;121:4127-4137. DOI: 10.1172/JCI46458
  28. 28. Zhang Z, et al. A variant OSR1 allele which disturbs OSR1 mRNA expression in renal progenitor cells is associated with reduction of newborn kidney size and function. Human Molecular Genetics. 2011;20:4167-4174. DOI: 10.1093/hmg/ddr341
  29. 29. Cheng Y, Vapurcuyan A, Shahidullah M, Aleksunes LM, Pelis RM. Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metabolism & Disposition. 2012;40:617-624. DOI: 10.1124/dmd.111.042036
  30. 30. Flister MJ, et al. Identifying multiple causative genes at a single GWAS locus. Genome Research. 2013;23:1996-2002. DOI: 10.1101/gr.160283.113
  31. 31. Barlassina C, Schork NJ, Manunta P, et al. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney International. 2000;57:1083-1090. DOI:
  32. 32. Morrison AC, Bray MS, Folsom AR, Boerwinkle E. ADD1 460 W allele associated with cardiovascular disease in hypertensive individuals. Hypertension. 2002;39:1053-1057. DOI:
  33. 33. Zafarmand MH, Van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. AlphaAdducin Gly460Trp variant increases the risk of stroke in hypertensive Dutch women. Hypertension. 2008;51:1665-1670. DOI: 10.1161/HYPERTENSIONAHA
  34. 34. Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmunity Reviews. 2010;9:830-834. DOI: 10.1016/j.autrev.2010.07.016
  35. 35. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: A growing challenge. The New England Journal of Medicine. 2007;356:213-215. DOI: 10.1056/NEJMp068177
  36. 36. Altshuler D, et al. The common PPARg Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics. 2000;26:76-80. DOI: 10.1038/79216
  37. 37. Gloyn AL, et al. Large scale association studies of variants in genes encoding the pancreatic b-cell K-ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with increased risk of type 2 diabetes. Diabetes. 2003;52:568-572. DOI:
  38. 38. Prokopenko I, McCarthy MI, Lindgren CM. Type 2 diabetes: New genes, new understanding. Trends in Genetics. 2008;24:613-621. DOI: 0.1016/j.tig.2008.09.004
  39. 39. Grant SFA, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics. 2006;38:320-323. DOI: 10.1038/ng1732
  40. 40. Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889-894. DOI: 10.1126/science.1141634
  41. 41. Grarup N, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: Validation and extension of genome-wide association studies. Diabetes. 2007;56:3105-3111. DOI: 10.2337/db07-0856
  42. 42. Pascoe L, et al. Common variants of the novel type 2 diabetes genes, CDKAL1 and HHEX/IDE, are associated with decreased pancreatic b-cell function. Diabetes. 2007;56:3101-3104. DOI: 10.2337/db07-0634
  43. 43. Grarup N, et al. Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes. 2008;57:2534-2540. DOI: 10.2337/db08-0436
  44. 44. Barroso I, et al. Dominant negative mutations in human PPARg associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883. DOI: 10.1038/47254
  45. 45. Gloyn AL, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. The New England Journal of Medicine. 2004;350:1838-1849
  46. 46. Maestro MA, et al. Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. Endocrine Development. 2007;12:33-45. DOI: 10.1159/0000109603
  47. 47. Domenech E, et al. Wolfram/DIDMOAD syndrome, a heterogenic and molecularly complex neurodegenerative disease. Pediatric Endocrinology Reviews. 2006;3:249-257
  48. 48. Zeggini E, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics. 2008;40:638-645. DOI: 10.1038/ng.120
  49. 49. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nature Immunology. 2011;12:204-212. DOI: 10.1038/ni.2001
  50. 50. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213. DOI: 10.1016/S0140-6736(11)61931-4
  51. 51. Ol KK, Agachan B, Gormus U, Toptas B, Isbir T. Cox-2 gene polymorphism and IL-6 levels in coronary artery disease. Genetics and Molecular Research. 2011;10:810-816. DOI: 10.4238/vol10-2gmr967
  52. 52. Christina LW, Leslie AL, Brendan JK. Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: The Candidate Gene Association Resource (CARe). Blood. 2011;117:268-275. DOI: 10.1182/blood-2010-06-289546
  53. 53. Meletta R, Slavik R, Mu L, et al. Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis. Nuclear Medicine and Biology. 2017;47:31-43. DOI: 10.1016/j.nucmedbio.2017.01.001
  54. 54. Tur J, Chapalamadugu KC, Padawer T, et al. Deletion of Kvβ1.1 subunit leads to electrical and haemodynamic changes causing cardiac hypertrophy in female murine hearts. Experimental Physiology. 2016;101:494-508. DOI: 10.1113/EP085405
  55. 55. Mollace V, Gliozzi M, Musolino V, et al. Oxidized LDL attenuates protective autophagy and induces apoptotic cell death of endothelial cells: Role of oxidative stress and LOX-1 receptor expression. International Journal of Cardiology. 2015;184:152-158. DOI: 10.1016/j.ijcard.2015.02.007
  56. 56. Biocca S, Falconi M, Filesi I, et al. Functional analysis and molecular dynamics simulation of LOX-1 K167N polymorphism reveal alteration of receptor activity. PLoS One. 2009;4:e4648. DOI: 10.1371/journal.pone.0004648
  57. 57. Fedele F, Mancone M, Chilian WM, et al. Role of genetic polymorphisms of ion channels in the pathophysiology of coronary microvascular dysfunction and ischemic heart disease. Basic Research in Cardiology. 2013;108:387. DOI: 10.1007/s00395-013-0387-4
  58. 58. Fedele F, Severino P, Bruno N, et al. Role of ion channels in coronary microcirculation: A review of the literature. Future Cardiology. 2013;9:897-905. DOI: 10.2217/fca.13.65
  59. 59. Pozsgai G, Bodkin JV, Graepel R, Bevan S, Andersson DA, Brain SD. Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo. Cardiovascular Research. 2010;87:760-768. DOI: 10.1093/cvr/cvq118
  60. 60. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, et al. Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. The Journal of Physiology. 2010;588:3277-3293. DOI: 10.1113/jphysiol.2010.192823
  61. 61. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacological Reviews. 2005;57:473-508. DOI: 10.1124/pr.57.4.10
  62. 62. Lee S, Yang Y, Tanner MA, Li M, Hill MA. Heterogeneity in Kv7 channel function in the cerebral and coronary circulation. Microcirculation. 2015;22:109-121. DOI: 10.1111/micc.12183
  63. 63. Ekmekci A, Güngör B, Özcan KS, et al. Evaluation of coronary microvascular function and nitric oxide synthase intron 4a/b polymorphism in patients with coronary slow flow. Coronary Artery Disease. 2013;24:461-467. DOI: 10.1097/MCA.0b013e328363258c
  64. 64. Akasaka T, Sueta D, Arima Y, et al. Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. The American Journal of Physiology-Heart and Circulatory Physiology. 2016;311:H1409-H1415. DOI: 10.1152/ajpheart.00473.2016
  65. 65. Akasaka T, Hokimoto S, Sueta D, et al. Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder. The American Journal of Physiology-Heart and Circulatory Physiology. 2016;310:H1494-H1500. DOI: 10.1152/ajpheart.00911.2015
  66. 66. Priestley JR, Kautenburg KE, Casati MC, et al. The NRF2 knockout rat: A new animal model to study endothelial dysfunction, oxidant stress, and microvascular rarefaction. The American Journal of Physiology-Heart and Circulatory Physiology. 2016;310:H478-H487. DOI: 10.1152/ajpheart.00586.2015
  67. 67. Mistry RK, Murray TV, Prysyazhna O, et al. Transcriptional regulation of cystathionine-γ-lyase in endothelial cells by NADPH oxidase 4-dependent signaling. The Journal of Biological Chemistry. 2016;291:1774-1788. DOI: 10.1074/jbc.M115.685578
  68. 68. Ockaili R, Natarajan R, Salloum F, et al. HIF-1 activation attenuates postischemic myocardial injury: Role for heme oxygenase-1 in modulating microvascular chemokine generation. The American Journal of Physiology-Heart and Circulatory Physiology. 2005;289:H542-548. DOI: 10.1152/ajpheart.00089.2005
  69. 69. Meijles DN, Fan LM, Ghazaly MM, Howlin B, Krönke M, Brooks G, Li JM. p22phox C242T single-nucleotide polymorphism inhibits inflammatory oxidative damage to endothelial cells and vessels. Circulation. 2016;133:2391-2403. DOI: 10.1161/CIRCULATIONAHA.116.021993
  70. 70. St Hilaire C, Ziegler SG, Markello TC, et al. NT5E mutations and arterial calcifications. The New England Journal of Medicine. 2011;364:432-442. DOI: 10.1056/NEJMc1102515#SA1
  71. 71. Markello TC, Pak LK, St Hilaire C, et al. Vascular pathology of medial arterial calcifications in NT5E deficiency: Implications for the role of adenosine in pseudoxanthoma elasticum. Molecular Genetics and Metabolism. 2011;103:44-50. DOI: 10.1016/j.ymgme.2011.01.018
  72. 72. Yoshino S, Cilluffo R, Best PJ, Atkinson EJ, et al. Single nucleotide polymorphisms associated with abnormal coronary microvascular function. Coronary Artery Disease. 2014;25:281-289. DOI: 10.1097/MCA.0000000000000104
  73. 73. Sim X1, Jensen RA, Ikram MK, Cotch MF, et al. Genetic loci for retinal arteriolar microcirculation. PLoS One. 2013;8:e65804. DOI: 10.1371/journal.pone.0065804
  74. 74. Ikram MK, Sim X, Jensen RA, et al. Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. PLoS Genetics. 2010;6:e1001184. DOI: 10.1371/journal.pgen.1001184
  75. 75. Olivotto I, Girolami F, Sciagra` R, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. Journal of the American College of Cardiology. 2011;58:839-848. DOI: 10.1016/j.jacc.2011.05.018
  76. 76. Spoladore R, Fisicaro A, Faccini A, Camici PG. Coronary microvascular dysfunction in primary cardiomyopathies. Heart. 2014;100:806-813. DOI: 10.1136/heartjnl-2013-304291
  77. 77. Leopold JA. Microvascular dysfunction: Genetic polymorphisms suggest sex-specific differences in disease phenotype. Coronary Artery Disease. 2014;25:275-276. DOI: 10.1097/MCA.0000000000000122
  78. 78. Fisher SA. Vascular smooth muscle phenotypic diversity and function. Physiological Genomics. 2010;42A:169-187. DOI: 10.1152/physiolgenomics.00111.2010
  79. 79. Edwards AG, Rees ML, Gioscia RA, Zachman DK, Lynch JM, Browder JC, Chicco AJ, Moore RL. PKC-permitted elevation of sarcolemmal KATP concentration may explain female-specific resistance to myocardial infarction. The Journal of Physiology. 2009;587:5723-5737. DOI: 10.1113/jphysiol.2009.181040
  80. 80. van de Hoef TP, van Lavieren MA, Damman P, et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. Circulation: Cardiovascular Interventions. 2014;7:301-331. DOI: 10.1161/CIRCINTERVENTIONS.113.001049


  • No conflict of interest to declare, no relationship with industry.

Written By

Francesco Fedele, Mariateresa Pucci and Paolo Severino

Submitted: 15 December 2016 Reviewed: 08 May 2017 Published: 06 September 2017